Fucoxanthin
1. Identity: Chemical and Botanical Characterization
1.1 Nomenclature and Classification
Fucoxanthin is a naturally occurring marine carotenoid, also known as marine xanthophyll, and is abundantly found as a pigment in the chloroplasts of brown algae. It is classified under xanthophylls—oxygenated carotenes, which contain one or more oxygen molecules. First isolated in 1914 by Willstätter and Page, fucoxanthin is an orange-colored xanthophyll pigment derived from brown algae and microalgae.
Its systematic IUPAC chemical name is 3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-carotene-8-one. The chemical formula of fucoxanthin is C₄₂H₅₈O₆, which corresponds to a molecular weight of 658.9 g/mol.
1.2 Structural Features
Similar to other carotenoids, fucoxanthin possesses unique characteristic features of an unusual allenic bond, a 5,6-monoepoxide, nine conjugated double bonds, and oxygenic functional groups. The oxygenic functional groups consisting of epoxy, hydroxyl, carboxyl, and carbonyl moieties exceptionally express the superiority of fucoxanthin over other carotenoids.
Fucoxanthin has a highly unique structure that contains both an epoxide bond and hydroxyl groups along with an allenic bond (two adjacent carbon-carbon double bonds) and a conjugated carbonyl group (carbon-oxygen double bond) in the polyene chain. All of these features provide fucoxanthin with powerful antioxidant activity.
Fucoxanthin can occur in a cis or trans configuration. However, the trans isomer has better stability, comprising 90% of naturally found fucoxanthin and has more potent antioxidant activity than the cis isomer.
1.3 Natural Sources and Distribution
Fucoxanthin is the major carotenoid pigment in marine ecosystems, representing 10% of the total carotenoid production. This yellow-orange pigment is produced by Chromista algae, a group composed of all brown and golden-brown macro and microalgae such as diatoms, haptophytes, dinophytes and brown seaweeds. It is found in high content in taxons such as Phaeophyceae, Haptophyta, Bacillariophyceae, and Chrysophyceae, and to a lesser extent in Rhodophyta, Raphidophyceae, and Dinophyta.
It is prevalent in brown seaweed because it functions as a light-harvesting complex for algal photosynthesis and photoprotection. In macroalgal plastids, fucoxanthin acts like an antenna for light harvesting and energy transfer in the photosystem light harvesting complexes. Fucoxanthin absorbs light primarily in the blue-green to yellow-green part of the visible spectrum, peaking at around 510–525 nm and absorbing significantly in the range of 450 to 540 nm.
Commercially significant sources include: commercially available fucoxanthin is mainly from marine seaweeds such as Eisenia bicyclis, Fucus vesiculosus, Hijikia fusiformis, Saccharina japonica and Undaria pinnatifida, where some are the most common edible macroalgae in East and Southeast Asia and some European countries. Fresh macroalgae generally have higher fucoxanthin content compared with dried algae, which might be due to the loss of fucoxanthin during the drying process.
1.4 Stability Considerations
Fucoxanthin is readily vulnerable to any of the following factors, including light, heat, oxygen, enzymes, unsaturated lipids, and prooxidant molecules. Post-extraction stability studies of fucoxanthin recommend that its use at the industry level should be kept at a low temperature and free from heat and light as well, because it is vulnerable to all of these extrinsic factors.
2. Traditional and Historical Use
Fucoxanthin is a naturally occurring carotenoid of brown seaweed and some microalgae which have traditionally been used as popular dietary supplements in East Asian countries for generations. It is important to note that while fucoxanthin as an isolated compound is modern, the seaweeds that contain it carry long histories of traditional use.
While the explicit isolation and use of fucoxanthin as an individual compound is relatively recent, brown seaweeds rich in this pigment have been utilized for centuries in traditional herbal medicine, especially in East Asian cultures.
Traditional Chinese medicine used hot water extracts of several types of seaweed in the treatment of cancer. Additionally, the Japanese and Chinese cultures used seaweed to treat goiter and other glandular problems as long ago as 300 BC.
In ancient China, seaweed was known as "hai zao" and was documented in the Compendium of Materia Medica, a 16th-century medical text by Li Shizhen. Though the text didn't name fucoxanthin specifically, it praised seaweed for "clearing heat," "softening hard lumps," and supporting kidney health.
Historically, seaweeds have a traditional usage, especially in Asian countries, as herbal medicine for the treatment of tumors, neurodegenerative diseases, urinary problems or gastrointestinal issues. Brown seaweeds are extensively used as part of the regular diet in East Asia, particularly in Japan, China, and Korea. Despite their use in traditional Chinese and Japanese folk medicines, only in recent years have they been commercialized as nutritional supplements and pharmaceutical products.
In Japanese Kampo and Chinese herbal traditions, brown seaweeds were frequently combined with other botanicals such as ginger, licorice root, and ginseng in decoctions and tonics intended to harmonize the body's systems and boost immunity.
Macroalgae have been used for nutritional and medicinal purposes in many cultures throughout history and they are an important part of traditional diets, especially in Asian countries.
3. Key Constituents and Active Compounds
3.1 Fucoxanthin Itself as the Primary Bioactive
Fucoxanthin is the primary bioactive constituent of interest in brown seaweed extracts. Brown macroalgae are rich in various bioactive compounds such as fucoxanthin, phlorotannin, fucoidan, alginate, and laminarin. However, fucoxanthin specifically carries the xanthophyll carotenoid chemistry that underlies the mechanisms discussed in the literature.
3.2 Primary Metabolites: Fucoxanthinol and Amarouciaxanthin A
In vivo, fucoxanthin is hydrolyzed to fucoxanthinol in the intestine and further converted to amarouciaxanthin A in the liver, undergoing subsequent dehydrogenation, isomerization, and esterification before distribution into plasma, liver, adipose tissue, and heart.
Dietary fucoxanthin is readily hydrolyzed to fucoxanthinol by digestive enzymes of lipase and cholesterol esterase and further converted to amarouciaxanthin A by NAD(P)+-dependent dehydrogenases in the gastrointestinal tract and liver, respectively.
Human studies revealed fucoxanthinol to be the primary active metabolite, as opposed to the metabolite profile observed in mice (fucoxanthinol and amarouciaxanthin A). Bioavailability of fucoxanthinol in humans was significantly higher than in mice.
More than 80% of fucoxanthin metabolites were accumulated in abdominal white adipose tissue (WAT) when purified fucoxanthin-containing diet was given to mice. Bioavailability studies demonstrated the distribution and accumulation of the metabolite fucoxanthinol in various tissues, including the liver, lung, kidney, heart, spleen, epididymal, and adipose tissue, after the oral administration of dietary fucoxanthin in mice.
The bioavailability of fucoxanthin was also studied in human volunteers after the oral administration of kombu algae containing fucoxanthin. The study found fucoxanthinol but not fucoxanthin in human plasma, suggesting that fucoxanthin is rapidly converted to its metabolite after gastrointestinal absorption.
4. Mechanisms of Action
4.1 Antioxidant Activity
Fucoxanthin has a strong antioxidant capacity by scavenging singlet molecular oxygen and free radicals. The structure of the fucoxanthin allenic bond is unique and imparts functional health impacts such as antioxidant, anti-obesity, anti-inflammatory, and many more.
Fucoxanthin has Nrf2 activity, resulting in cytoprotective effects of antioxidant and anti-inflammatory activities, and anti-cancer activity with apoptotic induction. Nrf2 (nuclear factor erythroid 2–related factor 2) is a master transcription factor that upregulates the body's endogenous antioxidant enzyme systems.
4.2 Anti-Obesity and Thermogenic Mechanisms
Nutrigenomic studies reveal that fucoxanthin induces UCP1 in abdominal WAT mitochondria, leading to the oxidation of fatty acids and heat production in WAT. UCP1 (uncoupling protein 1) is situated in the mitochondrial inner cellular membrane and is usually found in brown adipose tissue (BAT); it is not expressed in WAT in the absence of any stimulation.
Fucoxanthin was found to promote not only UCP1 protein and mRNA expression but also β3-adrenergic receptor (Adrb3), which is responsible for lipolysis and thermogenesis. This increased sensitivity to sympathetic nerve stimulation may lead to a further up-regulation of fat oxidation in WAT.
Fucoxanthin has also been shown to decrease the expression of enzymes involved in lipid synthesis, such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC).
Fucoxanthin improves insulin resistance and decreases blood glucose levels through the regulation of cytokine secretions from WAT. The key structure of the anti-obesity effect is suggested to be the carotenoid end of the polyene chromophore, which contains an allenic bond and two hydroxyl groups.
4.3 Anti-Inflammatory Mechanisms
Fucoxanthin was found to inhibit NF-κB by decreasing the stimulation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a master regulator of inflammatory gene expression; its inhibition accounts for a large portion of fucoxanthin's anti-inflammatory profile.
4.4 Anticancer Mechanisms
Fucoxanthin suppresses tumor formation through various mechanisms, including inducing autophagy, inducing apoptosis, arresting the cell cycle at G1/G0, and enhancing gap junctional intercellular communication, involving different regulatory events in pathways such as the Akt/mTOR, Bcl-2, SAPK/JNK, JAK/STAT, NF-κB and MAPK pathways.
Fucoxanthin inhibits many cancer cell lines' proliferation, angiogenesis, migration, invasion, and metastasis. In addition, it modulates miRNA and induces cell cycle growth arrest, apoptosis, and autophagy. Moreover, the literature shows fucoxanthin's ability to inhibit cytokines and growth factors such as TNF-α and VEGF, which stimulates the activation of downstream signaling pathways such as PI3K/Akt autophagy, and pathways of apoptosis.
In adult T-cell leukemia cells, fucoxanthin has been shown to reduce expressions of XIAP and Bcl-2 while activating procaspase-9, -8, and -3, indicating classical induction of caspase-mediated apoptosis.
4.5 Hepatoprotective Mechanisms
Fucoxanthin can repair FFA-induced NAFLD via the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway and nuclear factor erythroid-2-related factor 2-mediated (Nrf2) signaling pathway, as well as by downregulating the expression of the Toll-like receptor 4-mediated (TLR4) signaling pathway.
4.6 Antidiabetic Mechanisms
Dietary fucoxanthin has been found to activate insulin signaling pathways and glucose transporter 4 (GLUT4) in the skeletal muscles of diabetic/obese KK-Ay mice, providing a molecular basis for its reported antidiabetic effects.
5. Scientific Evidence by Area of Use
5.1 Obesity and Body Weight Management
Preclinical evidence (animal models): Among the biological activities of fucoxanthin, anti-obesity is the most well-studied and most promising effect. This effect is primarily based on the upregulation of thermogenesis by uncoupling protein 1 expression and the increase in the metabolic rate induced by mitochondrial activation. Animal experiments clearly showed the anti-obesity effect of fucoxanthin.
Human clinical evidence: One of the most relevant clinical studies was carried out in Russia by Abidov et al. in 2010, in which the effect of Xanthigen (a supplement containing 2.4 mg fucoxanthin and 300 mg pomegranate seed oil) was evaluated on body weight, body fat, and lipid profile in premenopausal, obese women with and without nonalcoholic fatty liver disease (n=36) after 16 weeks of dosing. The study demonstrated reduced waist circumference in the NAFLD group (110.6 ± 1.6 cm vs 105.0 ± 5.6 cm, p < 0.05) and decreased body weight in both groups.
The combination of 300 mg pomegranate seed oil and 300 mg brown seaweed extract containing 2.4 mg fucoxanthin significantly resulted in the reduction of body weight and liver fat content in obese women who were treated for 16 weeks.
A separate Japanese randomized, double-blind, placebo-controlled study examined lower doses. That trial examined the effect of fucoxanthin (1 or 3 mg daily) in a double-blind placebo-controlled study; capsules were administered for 4 weeks to male and female Japanese adults with a BMI of more than 25 kg/m². Before and after treatment, body weight, body composition, abdominal fat area, and circumferences were evaluated. There was significant reduction of relative body weight, BMI, and visceral fat area in the 3 mg/day fucoxanthin group compared to the placebo group.
In obese women without diabetes, Xanthigen caused a reduction in body weight, and body and liver fat content. Moreover, plasma levels of the liver enzymes ALT, AST, and γ-glutamyltransferase (GGT) were all reduced by Xanthigen compared to placebo. Additionally, consuming Xanthigen and fucoxanthin enhanced the levels of resting energy expenditure (REE).
Evidence strength: Due to the small number of participants, the clinical evidence is exploratory in nature. These results would need to be confirmed by a larger sample size. Overall, the human evidence base for fucoxanthin in weight management is promising but remains limited by small trials, short durations, and the confounding presence of co-ingredients (such as pomegranate seed oil) in the best-known trials.
5.2 Non-Alcoholic Fatty Liver Disease (NAFLD)
Mechanism: Fucoxanthin can repair FFA-induced NAFLD via the AMPK, Nrf2, and TLR4 signaling pathways.
Clinical evidence: A double-blind, randomized controlled trial investigated the combination of low-molecular-weight fucoidan (LMF) and high-stability fucoxanthin (HSFx) in NAFLD patients. The study screened 70 patients aged 20 to 75 years with sonographic evidence of fatty liver. In this pilot study, the seaweed derivative mixture significantly reduced ALT, indicating that the combination of fucoidan and fucoxanthin might be a novel hepatoprotective supplement for NAFLD patients.
The FDA has approved fucoxanthin extracted from microalga as a new nutritional supplement that can be consumed at a dosage of 3 mg daily for an indefinite period or 5 mg fucoxanthin daily for up to 90 days.
Evidence strength: Preclinical (cell and animal) data on hepatoprotective effects of fucoxanthin are consistent across multiple studies. Human evidence is preliminary, generally in the form of small pilot studies, often with combination products, and further large-scale trials are needed.
5.3 Diabetes and Glycemic Control
Preclinical evidence: Fucoxanthin, found in brown seaweeds such as Undaria pinnatifida (Wakame) and Saccharina japonica (Makonbu), demonstrated anti-obesity and anti-diabetic effects in animal models. As a molecular mechanism for anti-diabetic effect, dietary fucoxanthin activated insulin signaling pathways and glucose transporter 4 (GLUT4) in the skeletal muscles of diabetic/obese KK-Ay mice.
Clinical evidence: A clinical trial carried out in Japan and published in 2017 by Mikami et al. evaluated the effect of oil from the Akamoku algae (Sargassum horneri) enriched with fucoxanthin at a dose of 2.0 mg/day, administered for eight weeks in adults with normal and overweight (n = 20). A decrease in HbA1c was observed in the group that received fucoxanthin, which was directly related to the serum level of fucoxanthinol.
Evidence strength: Preclinical mechanistic evidence is solid. Human clinical evidence is sparse, from small studies, and not consistently replicated at scale.
5.4 Cancer (Preclinical Focus)
Fucoxanthin has antioxidant and anti-inflammatory properties but also several anticancer effects. Fucoxanthin induces cell growth arrest, apoptosis, and/or autophagy in several cancer cell lines as well as in animal models of cancer. Fucoxanthin treatment leads to the inhibition of metastasis-related migration, invasion, epithelial–mesenchymal transition, and angiogenesis. Fucoxanthin also affects the DNA repair pathways, which could be involved in the resistance phenotype of tumor cells.
Anticancer activity has been found in glioblastoma, colon cancer, bladder cancer, prostate cancer, liver cancer, leukemia, gastric cancer, cervical cancer, melanoma, osteosarcoma, breast cancer, and lung cancer.
Anti-proliferative effect and apoptosis induction by fucoxanthin in human colon cancer cells (Caco-2, HT-29 and DLD-1) were observed by Hosokawa et al. (2004). Combined treatment with 3.8 µM fucoxanthin and 10 µM troglitazone, a specific ligand for PPARγ, effectively decreased the viability of Caco-2 cells, whereas separate treatments with these same concentrations of fucoxanthin or troglitazone alone did not affect cell viability. These findings indicate that fucoxanthin may act as a chemopreventive and/or chemotherapeutic carotenoid in colon cancer cells by modulating cell viability in combination with troglitazone.
Evidence strength: Essentially all cancer evidence is in vitro or in animal models. There are no published large-scale human clinical trials demonstrating anticancer efficacy of fucoxanthin in humans. The preclinical data is mechanistically interesting but cannot be translated directly to clinical recommendations.
5.5 Neuroprotection
Thanks to its unique chemical structure, fucoxanthin exhibits numerous healthy properties in diabetes, obesity, cardiovascular diseases, cancer, and neurodegenerative diseases. Recent studies have shown the ability of fucoxanthin to counteract amyloid protein aggregation, oxidative stress, neuroinflammation, neuronal death, and neurotransmission dysregulation in different experimental models of psychiatric disorders, acute brain injury, and Alzheimer's and Parkinson's disease.
Fucoxanthinol also shared similar neuroprotective effects as fucoxanthin against the neurotoxicity generated by oligomeric amyloid-beta and 6-OHDA, suggesting a potential neuroprotective contribution to the action of fucoxanthin administered as a food supplement in in vivo experimental models. These results encourage further research to evaluate the bioavailability of fucoxanthinol and other metabolites of fucoxanthin at the brain level to elucidate the dietary neuroprotective potential of fucoxanthin.
Evidence strength: Neuroprotective evidence is confined almost entirely to cell culture and rodent models. No human clinical trials demonstrating neuroprotective effects of fucoxanthin supplementation have been identified in peer-reviewed literature.
5.6 Antioxidant and Anti-Inflammatory Activity
Fucoxanthin has a strong antioxidant capacity by scavenging singlet molecular oxygen and free radicals. It also exerts an anti-inflammatory effect. These properties are well-documented at the biochemical and cellular level. Numerous components of seaweeds have demonstrated varying degrees of antioxidant capability and carcinogen inhibition in vitro and in vivo.
Evidence strength: Strong mechanistic and preclinical evidence. Direct demonstration of antioxidant/anti-inflammatory benefit as a clinical endpoint in human trials is limited.
5.7 Gut Microbiota Modulation
Fucoxanthin modulates gut microbial composition through a duplibiotic effect, linking its metabolism to host-microbiota interactions. This emerging area of research is currently based on preclinical findings and requires further investigation in human subjects.
6. Body Systems and Health Areas
Based on the peer-reviewed literature, fucoxanthin has been investigated across the following body systems:
- Adipose tissue and metabolic system: UCP1-mediated thermogenesis in white adipose tissue, regulation of lipid synthesis enzymes (FAS, ACC), adipokine modulation.
- Hepatic system: Hepatoprotective effects against fatty liver disease through AMPK/Nrf2/TLR4 pathways; reduction of liver enzymes ALT, AST, and GGT in clinical settings.
- Endocrine/glycemic system: Activation of GLUT4 and insulin signaling pathways; reduction of HbA1c in preliminary human data.
- Immune and inflammatory system: NF-κB and MAPK pathway inhibition; TNF-α and VEGF suppression.
- Oncological/cellular: Multiple cancer cell lines in vitro (preclinical only); induction of apoptosis, autophagy, and cell cycle arrest.
- Nervous system: Counteraction of amyloid-beta aggregation and oxidative neuronal stress; neuroprotection in animal models of Alzheimer's and Parkinson's disease (preclinical only).
- Cardiovascular system: Cardiovascular and cerebrovascular protective effects have been reported in preclinical investigations.
7. Dosage Forms and Preparations
7.1 Dietary Sources
The primary dietary exposure to fucoxanthin occurs through consumption of brown seaweeds such as wakame (Undaria pinnatifida) and kombu (Saccharina japonica), both of which are staples of East Asian diets. Although some studies have shown the bioavailability of fucoxanthin in brown seaweeds to be low in humans, many studies have suggested that a dietary combination of fucoxanthin and edible oil or lipid could increase the absorption rate of fucoxanthin.
7.2 Commercial Supplement Forms
Fucoxanthin is purified and standardized into a dietary supplement to optimize and enhance bioavailability. Users can access fucoxanthin in capsule or powder form or in combination with other compounds such as CLA, pomegranate oil, or MCT oil.
Fucoxanthin is lipid-soluble and requires careful encapsulation or emulsification to prevent degradation and enhance absorption. The combination of fucoxanthin with dietary fats or oils is not merely a formulation convenience; fucoxanthin mixed with lipids can remarkably improve its bioavailability, since fucoxanthin itself is lipophilic and when it interacts with other oils, it could enhance transportability through the cell membrane barrier and ultimately improve bioavailability.
Advanced delivery technologies under investigation include solid lipid nanoparticles (SLNs). Researchers have encapsulated fucoxanthin in solid lipid nanoparticles (SLNs) utilizing health-safe materials. SLNs have demonstrated a nanoscale size of approximately 249 nm, along with high encapsulation efficiency and loading capacity in lipid. To further improve bioavailability, enteric coatings have been applied to freeze-dried SLNs, effectively protecting fucoxanthin from gastric degradation.
7.3 Dosages Used in Clinical Studies
The following dosages are drawn directly from published studies cited in this article:
- The Abidov et al. (2010) Xanthigen trial used a formulation containing 2.4 mg fucoxanthin combined with 300 mg pomegranate seed oil, administered over 16 weeks in obese premenopausal women.
- A Japanese double-blind placebo-controlled trial used 1 or 3 mg fucoxanthin daily, administered for 4 weeks to adults with BMI over 25 kg/m².
- A 2017 Japanese trial used oil from Sargassum horneri enriched with fucoxanthin at a dose of 2.0 mg/day for eight weeks in adults with normal and overweight (n=20).
- Fucoxanthinol appears to be the most active metabolite in humans; its maximum concentration, time to maximum concentration, and half-life were 44.2 nM/mL, 4.0 and 7.0 hours, respectively. A 31 mg dose (0.52 mg/kg body weight) was found to be safe and sufficient to induce health benefits in one pharmacokinetic study.
- The FDA has approved fucoxanthin extracted from microalgae as a new nutritional supplement consumable at 3 mg daily for an indefinite period or 5 mg fucoxanthin daily for up to 90 days.
8. Safety, Bioavailability, and Notable Considerations
8.1 General Safety Profile
Fucoxanthin is a naturally occurring carotenoid of brown seaweed and some microalgae which have traditionally been used as popular dietary supplements in East Asian countries for generations. This long traditional usage supports the safety of fucoxanthin upon consumption.
Animal studies have shown that fucoxanthin supplementation has no adverse effects. However, investigation of the safety of fucoxanthin consumption in humans is lacking. Clinical trials are required to assess the safety of fucoxanthin in conjunction with the study of mechanisms by which fucoxanthin exhibits its health benefits.
Fucoxanthin has demonstrated no observable toxicity in rodent studies, even at a substantially high dose of 2000 mg/kg/BW/day.
8.2 Rodent Toxicology Findings Requiring Clarification
A 28-day oral toxicity study in rats showed no obvious toxicity. It should, however, be noted that significant increases in total cholesterol blood levels were observed at doses of 10 mg/kg/day or higher. Similar observations have been reported in a repeated-dose study in mice at doses of 500 and 1000 mg/kg. The underlying mechanism by which fucoxanthin induces hypercholesterolemia in rodents should be elucidated to confirm its safety. These findings have not been replicated in the limited human studies conducted to date, but remain a noted observation in animal toxicology.
8.3 Bioavailability Challenges
The clinical application of fucoxanthin is significantly hindered by its poor aqueous solubility and low bioavailability, primarily attributed to the rapid degradation of free fucoxanthin in the gastrointestinal tract and suboptimal tissue distribution, which restrict its ability to exert target-specific effects in metabolic tissues. These limitations result in ineffective outcomes with low-dose supplementation.
Additionally, fucoxanthin modulates gut microbial composition through a duplibiotic effect, linking its metabolism to host-microbiota interactions. Lipid-, polysaccharide-, and protein-based delivery systems have been developed due to low oral bioavailability.
8.4 Species-Dependent Metabolism
Fucoxanthin pharmacokinetics have been shown to be species-dependent. Human studies revealed fucoxanthinol to be the primary active metabolite, as opposed to the metabolite profile observed in mice (fucoxanthinol and amarouciaxanthin A). This distinction is important when interpreting animal study results, as the relative contribution of each metabolite to observed biological effects may differ between rodent models and humans.
8.5 Known Interactions
At the time of writing, there were no well-known supplement or food interactions with this supplement. As of the last update, no reported interactions between this supplement and medicines were found. It is possible that unknown interactions exist.
8.6 Formulation and Stability Notes
Post-extraction stability studies of fucoxanthin recommend that its use at the industry level should be kept at a low temperature and free from heat and light as well, because it is vulnerable to all of these extrinsic factors. A dietary combination of fucoxanthin and edible oil or lipid could increase the absorption rate of fucoxanthin.
9. Regulatory and Commercial Status
Supplied by Algatechnologies Inc., FucoVitalâ„¢ was the first fucoxanthin health food product approved by the US Food and Drug Administration. The FDA has approved fucoxanthin extracted from the microalga as a new nutritional supplement that can be consumed at a dosage of 3 mg daily for an indefinite period or 5 mg fucoxanthin daily for up to 90 days.
Based on recent scientific literature, fucoxanthin extracted from edible brown seaweed commercially has been suggested for pharmaceutical or medicinal uses, as it is safe and has no toxicity upon administration. However, the availability of fucoxanthin for industrial uses is unfortunately limited, and a chemical process for fucoxanthin synthesis is complex and eventually expensive for endpoint users.
10. Summary of Evidence Quality
The following is an honest characterization of the state of evidence across major application areas:
- Anti-obesity / metabolic: Most extensively studied; positive results from multiple small human RCTs (predominantly involving combination products), strongly supported by animal and mechanistic data. Human evidence is promising but not yet definitive due to small sample sizes and short follow-up.
- Hepatoprotective (NAFLD): Consistent preclinical data with mechanistic clarity. A small number of pilot human studies show reduced liver enzymes, but sample sizes are insufficient for firm conclusions.
- Antidiabetic: Strong preclinical mechanistic data (GLUT4, insulin signaling). Preliminary human evidence exists (one small n=20 trial) but is insufficient to draw clinical conclusions.
- Anticancer: Extensive in vitro data across numerous cancer cell lines; animal model support. No human clinical trials. Evidence must not be extrapolated to clinical recommendations.
- Neuroprotection: Primarily cell culture and animal model data. No human trials identified.
- Antioxidant / anti-inflammatory: Well-characterized at the biochemical and cellular level; clinical endpoint evidence in humans is limited.
The results of animal studies showed that fucoxanthin had potential value in preventing and treating lifestyle-related diseases, as obesity, diabetes, cancer, cardiovascular disease, and other chronic diseases. Though there are a few studies in human subjects, more clinical trials should be conducted.
References
- Brown Algae as Functional Food Source of Fucoxanthin: A Review — PMC / NCBI
- A Systematic Review on Marine Algae-Derived Fucoxanthin: An Update of Pharmacological Insights — PMC / NCBI
- Fucoxanthin from Algae to Human, an Extraordinary Bioresource: Insights and Advances in up and Downstream Processes — PMC / NCBI
- Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy — PMC / NCBI
- Anti-Obesity Activity of the Marine Carotenoid Fucoxanthin — PMC / NCBI
- Fucoxanthin: A Promising Medicinal and Nutritional Ingredient — PMC / NCBI
- A Review of the Effects of Fucoxanthin on NAFLD — PMC / NCBI
- Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation — PMC / NCBI
- The anticancer effects and mechanisms of fucoxanthin combined with other drugs — PMC / NCBI
- Antioxidant and Neuroprotective Effects of Fucoxanthin and Its Metabolite Fucoxanthinol: A Comparative In Vitro Study — PMC / NCBI
- Fucoxanthin: A Comprehensive Review on Digestion, Biotransformation, Microbiome Interaction, and Targeted Delivery — Journal of Agricultural and Food Chemistry / ACS Publications
- Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/TLR4 Signaling Pathway — PMC / NCBI
- Innovative Approaches to Fucoxanthin Delivery: Characterization and Bioavailability of Solid Lipid Nanoparticles — PMC / NCBI
- Fucoxanthin Loaded in Palm Stearin- and Cholesterol-Based Solid Lipid Nanoparticle-Microcapsules — PMC / NCBI
- Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-Ay Mice — PMC / NCBI
- Low-molecular-weight fucoidan and high-stability fucoxanthin decrease serum alanine transaminase in patients with NAFLD — Advances in Digestive Medicine / Wiley
- Seaweed Fucoxanthin Supplementation Improves Obesity Parameters in Mild Obese Japanese Subjects — Functional Foods in Health and Disease
- Fucoxanthin, a Marine Carotenoid: Metabolism and Bioactivities Relevant to Human Health — Marine Drugs / MDPI
- Health benefits of fucoxanthin in the prevention of chronic diseases — ScienceDirect
- Fucoxanthin in the management of obesity and its related disorders — ScienceDirect
- Fucoxanthin — ScienceDirect Topics Overview
- Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion — ClinicalTrials.gov Protocol NCT03613740
- Fucoxanthin — Wikipedia (chemical identity summary)
- Fucoxanthin — PeaceHealth Health Information Library (TraceGains)
- Seaweed: Uses, Benefits & Dosage — Drugs.com
- Fucoxanthin-Loaded Solid Lipid Nanoparticles Exert Potent Therapeutic Efficacy in High-Fat Diet Induced Obesity in Mice — PMC / NCBI
- Marine Algae-Derived Fucoxanthin — Encyclopedia MDPI
- Anti-Obesity Therapy by Food Component: Unique Activity of Marine Carotenoid, Fucoxanthin — Symbiosis Online Publishing
Go back